The Pharma Letter23h
Huge backing for Noema’s neuroscience goal
Noema Pharma, a Swiss biotech targeting debilitating central nervous system (CNS) disorders, has announced the successful ...
PharmiWeb23h
Noema Pharma extends Series B financing round, closing at CHF130 Million ($147 Million)
Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced the successful close of a Series B extension financing round with an investment ...